Spots Global Cancer Trial Database for A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
Official Title: A Randomized, Dose - Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
Study ID: NCT00359840
Conditions
Interventions
Study Description
Brief Summary: To assess the clinical effective dose of KRN321 administered with once triweekly schedule.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tokai region, Aichi, , Japan
Shikoku region, Ehime, , Japan
Kyusyu region, Fukuoka, Kumamoto, , Japan
Hokkaido region, Hokkaido, , Japan
Kinki region, Kyoto, Osaka, Nara, , Japan
Tohoku region, Miyagi, , Japan
Hokuriku region, Niigata, Ishikawa, , Japan
Kanto region, Tochigi, Saitama, Tokyo, Kanagawa, , Japan
Contact Details
Name: Nagahiro Saijo, MD
Affiliation: National Cancer Center Hospital East
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
